Brain and Spinal Tumor Cancer Trials

A072301 | 26.0577: PHASE III TRIAL OF RADIOTHERAPY FOLLOWED BY ADJUVANT TEMOZOLOMIDE IN COMBINATION WITH THE IDH INHIBITOR VORASIDENIB VS. PLACEBO IN IDH-MUTATED NEWLY-DIAGNOSED GRADE 3 ASTROCYTOMAS

Principal Investigator

Guneet Sarai, MD

Phase

III

Description

This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill tumor cells and slow down or stop tumor growth. Vorasidenib citrate blocks the proteins made by the mutated IDH1 and IDH2 genes, which may help keep tumor cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Adding vorasidenib to the usual treatment, temozolomide, may be more effective than temozolomide alone in treating patients with newly diagnosed grade 3 astrocytoma after radiation therapy.

Find more information at ClinicalTrials.gov

25.0772: RANDOMIZED PHASE II TRIAL OF ANTI-LAG-3 AND ANTI-PD-1 BLOCKADE VS. SOC IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Principal Investigator

Guneet Sarai, MD

Phase

II

Description

This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Relatlimab and nivolumab may be safe, tolerable, and/or effective compared to standard of care lomustine in treating patients with recurrent glioblastoma

Find more information at ClinicalTrials.gov

25.0244: No Perioperative Dexamethasone in Brain Metastases

Principal Investigator

Akshitkumar Mistry, MD

Phase

NA

Description

In this clinical study, we will treat patients scheduled to undergo resection of a brain metastasis without dexamethasone perioperatively.

Find more information at ClinicalTrials.gov

25.0073: A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 as a Single Agent in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch Repair

Principal Investigator

Rebecca Redman, MD

Phase

I/II

Description

The goal of this cancer trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study.

Find more information at ClinicalTrials.gov

08.0388: Protocol for the Cancer Database and Specimen Repository (CDSR) at the Brown Cancer Center (Previous Lung Repository).

Principal Investigator

Rebecca Redman, MD

Description

The mission of the Cancer Database and Specimen Repository (CDSR) is to collect clinical information and samples of human specimens from cancer patients and from control patients for research, and to distribute specimens to researchers for the advancement of science.